Mounjaro (tirzepatide) works on two hormone pathways, GLP-1 and GIP, while semaglutide works only on GLP-1. This dual action may lead to greater effects on blood sugar control and weight loss in some patients, based on clinical studies, though responses can vary. Semaglutide has established evidence for diabetes control and, in certain approved indications, cardiovascular and kidney benefits. Both medicines can cause certain side effects and require medical supervision. The choice between them depends on your medical condition, history, and treatment goals, and should be made by your doctor.